title: Phase II clinical and endocrine study of Anandron (RU-23908) in advanced post-menopausal breast cancer.
authors.affiliation: University Department of Clinical Oncology, Newcastle General Hospital, Newcastle-Upon-Tyne, UK.
authors.forename: M J
authors.initials: MJ
authors.lastname: Millward
authors.forename: B M
authors.initials: BM
authors.lastname: Cantwell
authors.forename: M
authors.initials: M
authors.lastname: Dowsett
authors.forename: J
authors.initials: J
authors.lastname: Carmichael
authors.forename: A L
authors.initials: AL
authors.lastname: Harris
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000473:pathology; D004341:Drug Evaluation; D004958:Estradiol / Q000097:blood; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use*; D048289:Imidazolidines; D007986:Luteinizing Hormone / Q000097:blood; D008593:Menopause; D008875:Middle Aged; D012738:Sex Hormone-Binding Globulin / Q000032:analysis
chemical_list: D000970:Antineoplastic Agents; D007093:Imidazoles; D048289:Imidazolidines; D012738:Sex Hormone-Binding Globulin; D004958:Estradiol; C021277:nilutamide; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone